ESK981
- Generic Name
- ESK981
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C35H35N7O4S
- CAS Number
- 856691-93-5
- Unique Ingredient Identifier
- J8AY0Z4CBP
- Associated Conditions
- -
- Associated Therapies
- -
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT05988918
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03562507
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT03456804
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath